Cargando…
Safety and immunogenicity of a quadrivalent influenza vaccine in adults aged 60 years or above: a phase III randomized controlled clinical study
To control seasonal influenza epidemics in elders, a quadrivalent, inactivated, split-virion influenza vaccine (IIV4) comprising A and B lineages is produced for young individuals and adults aged ≥60 years. In this phase III, randomized, double-blind, active-controlled trial, we compared safety and...
Autores principales: | Fan, Renfeng, Huang, Xiaoyuan, Nian, Xuanxuan, Ou, Zhiqiang, Zhou, Jian, Zhang, Jiayou, Zeng, Peiyu, Zhao, Wei, Deng, Jinglong, Chen, Wei, Chen, Shaomin, Duan, Kai, Chen, Yingshi, Li, Xinguo, Zhang, Jikai, Yang, Xiaoming |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8920214/ https://www.ncbi.nlm.nih.gov/pubmed/34473607 http://dx.doi.org/10.1080/21645515.2021.1967041 |
Ejemplares similares
-
Safety and immunogenicity of a quadrivalent, inactivated, split-virion influenza vaccine (IIV4-W) in healthy people aged 3-60 years: a phase III randomized clinical noninferiority trial
por: Huang, Xiaoyuan, et al.
Publicado: (2022) -
Immunogenicity and safety of quadrivalent inactivated influenza vaccine in children aged 6 to 35 months: A systematic review and meta-analysis
por: Wei, Xia, et al.
Publicado: (2023) -
Sex-specific differences of humoral immunity and transcriptome diversification in older adults vaccinated with inactivated quadrivalent influenza vaccines
por: Yang, Jing, et al.
Publicado: (2021) -
Immunogenicity and safety of the quadrivalent inactivated split-virion influenza vaccine in populations aged ≥ 3 years: A phase 3, randomized, double-blind, non-inferiority clinical trial
por: Chen, Jianmin, et al.
Publicado: (2023) -
Reply letter to “Immunogenicity and safety of a quadrivalent high-dose inactivated influenza vaccine compared with a standard-dose quadrivalent influenza vaccine in healthy people aged 60 years or older: a randomized Phase III trial”
por: Hadigal, Sanjay, et al.
Publicado: (2022)